
Oncology NEWS International
- Oncology NEWS International Vol 15 No 11
- Volume 15
- Issue 11
New Product
BioLucent, Inc. has received 510(k)clearance from the FDA for its SAVIapplicator. The SAVI device offersa multicatheter, single-entry approachto breast brachytherapy.
ALISO VIEJO, California--BioLucent, Inc. has received 510(k)clearance from the FDA for its SAVIapplicator. The SAVI device offersa multicatheter, single-entry approachto breast brachytherapy.SAVI combines the tissue-sparingdosimetry of interstitial brachytherapywith the single-entry easeof intracavitary ("balloon") brachytherapy,the company said in a pressrelease
The applicator is for use in acceleratedpartial breast irradiation(APBI) treatment following alumpectomy. The device includesan expandable bundle of cathetersthat surround a central lumen. Theapplicator is placed into the lumpectomycavity through a small incision.The physician expands thecatheter bundle by turning a mechanismfrom outside the breast. Thecatheters expand to form an ellipsoidalshape inside the cavity. Deliveryof radiation through the device'sindividual catheters allowsthe physician to better contour andcontrol the radiation dose.
Articles in this issue
over 19 years ago
High ERCC1 Levels Predict Cisplatin Resistanceover 19 years ago
CT Screening Detects Curable Stage I Lung Cancerover 19 years ago
Triple-Negative Caโs Respond to Optimized Taxane Chemotherapyover 19 years ago
Avastin Approved as First-Line Rx of Nonsquamous NSCLCover 19 years ago
Rituxan Receives FDA Approval for 2 New NHL Indicationsover 19 years ago
Lapatinib Benefit Seen in Inflammatory Breast Cancerover 19 years ago
Sinking Health Care Ship Could Bring Down the Economyover 19 years ago
Breast Ultrasound Referrals Often Lack Important Infoover 19 years ago
FDA Okays Zolinza for CTCL Skin LesionsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































